UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 30 , 2018

VIVEVE MEDICAL, INC.

(Exact Name of Registrant as Specified in Charter)

 

 

Delaware

 

1-11388

 

04-3153858

(State or Other Jurisdiction of

Incorporation)

 

(Commission File Number)

 

(I.R.S. Employer

Identification No.)

 

 

345 Inverness Drive South, Building B, Suite 250,

Englewood, Colorado

 

80112

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (720) 696-8100

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 1.01 Entry Into a Material Definitive Agreement.

 

On June 4, 2018, Viveve Medical, Inc. (the “Company”) entered into a Settlement and License Agreement (the “Settlement Agreement”) with ThermiGen LLC and ThermiAesthetics LLC (“Thermigen,” collectively) and Dr. Red Alinsod (together with Thermigen, “Defendants”), resolving the Company’s patent litigation against Defendants. The litigation arose from the Company’s claim that Defendants were improperly using the Company’s patented technology without consent. Pursuant to the Settlement Agreement, the parties agreed to resolve all currently pending disputes between them, including seeking dismissal of the litigation captioned as Viveve, Inc. v. Thermigen LLC, et al., No. 2:16-1189 (E.D. Tex.), as well as the two inter partes review proceedings (Nos. 2018-0088 and 2018-0089), pending before the United States Patent and Trademark Office Patent Trial and Appeal Board.

 

Under the terms of the Settlement Agreement, Viveve grants to Defendants a non-exclusive, non-transferable license to U.S. Patent No. 8,961,511 and to any other patent claiming priority to or through U.S. Serial No. 11/704,067 for the current version of Thermigen’s ThermiVa system (which includes RF generators and consumables). Thermigen provided Viveve with a covenant not to sue it or its customers for infringement of intellectual property rights for which Thermigen or its Affiliates has pending U.S. patent applications (or applications that later claim priority to such applications) in the field of monopolar radiofrequency in vaginal tissue. Viveve and Thermigen also provided mutual releases for activity prior to the Settlement Agreement.

 

Under the Settlement Agreement, Thermigen agrees to make certain settlement payments to Viveve.  Thermigen also agrees to pay a running royalty based on net revenue received for sales, rental or lease of any Thermigen generator provided to a U.S. customer with ThermiVa functionality available (or that becomes available) and U.S. ThermiVa consumables revenue.

 

The foregoing is a brief description of the material terms of the Settlement Agreement, does not purport to be a complete description of the rights and obligations of the parties thereunder, and is qualified in its entirety by reference to the Settlement Agreement, which the Company intends to file as an exhibit to its Quarterly Report on Form 10-Q for the fiscal quarter ending June 30, 2018. The Company also intends to seek appropriate confidential treatment of certain terms and provisions of the Settlement Agreement in connection with the filing of such agreement, in accordance with the procedures of the Securities and Exchange Commission.

 

 

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.

 

On May 30, 2018, in connection with Patricia Scheller’s previously disclosed resignation from her position as Chief Executive Officer of the Company, the Company and Ms. Scheller entered into a Consulting Agreement, effective as of May 11, 2018 (the “Consulting Agreement”), pursuant to which Ms. Scheller will provide advisory services relating to the transition of duties and assisting with business matters for a period of 6 months, unless earlier terminated or extended by the parties. Ms. Scheller will receive a monthly fee of $16,000 for her services.

 

In addition, on May 30, 2018, under approval of the Board of Directors of the Company, the Company entered into a Separation Agreement and Release Agreement with Ms. Scheller, effective as of May 11, 2018 (the “Separation Agreement”). Pursuant to the Separation Agreement, Ms. Scheller is entitled to receive: (i) base salary continuation for 12 months, (ii) a monthly cash payment in an amount equal to the employer portion of her monthly health insurance premium until the earliest of 12 months following the date of termination, the expiration of her continuation coverage under COBRA or the date she becomes eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment, (iii) continued vesting of all stock options and other stock-based awards held by Ms. Scheller that would have vested had she remained employed through December 31, 2018, (iv) accelerated vesting of such awards for an additional six months following such date, and (v) extension of the period of exercisability of such awards for a  period of twelve months following the effective date of the Separation Agreement.

 

The foregoing descriptions of the terms of the Consulting Agreement and Separation Agreement do not purport to be complete and are qualified in their entirety by reference to the Consulting Agreement and Separation Agreement, which are filed as exhibits 10.1 and 10.2 to this Current Report on Form 8-K, and are incorporated herein by reference.

 

 

Item 8.01 Other Events.

 

On June 4, 2018, the Company issued a press release announcing its entry into the Settlement Agreement. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

 

 

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit

No.

  

Description

  

  

10.1

 

Consulting Agreement between the Company and Patricia Scheller, dated May 30, 2018, effective as of May 11, 2018

10.2

 

Separation Agreement between the Company and Patricia Scheller, dated May 30, 2018, effective as of May 11, 2018

99.1   Press Release, dated June 4, 2018, titled “Viveve Announces Settlement of Patent Infringement Litigation with Thermi.”

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 5, 2018 

Viveve Medical, Inc.

 

 

 

 

 

 

 

 

 

 

By:

/s/ Scott Durbin

 

 

 

Scott Durbin

Chief Executive Officer

 

 

Exhibit 10.1

 

CONSULTING AGREEMENT

 

 

Effective May 11, 2018, (the “Effective Date”) Patricia Scheller (“Consultant”) and Viveve Medical, Inc. (“Company”) agree as follows:

 

1.       Services; Payment; No Violation of Rights or Obligations . Consultant agrees to undertake and complete the Services (as defined in Exhibit A ) in accordance with and on the schedule specified in Exhibit A . As the only consideration due Consultant regarding the subject matter of this Agreement, Company will pay Consultant in accordance with Exhibit A . Unless otherwise specifically agreed upon by Company in writing (and notwithstanding any other provision of this Agreement), all activity relating to Services will be performed by and only by Consultant or by employees of Consultant and only those such employees who have been agreed upon in writing in advance by Company. Consultant agrees that Consultant will not (and will not permit others to) violate any agreement with or rights of any third party or, except as expressly authorized by Company in writing hereafter, use or disclose at any time Consultant’s own or any third party’s confidential information or intellectual property in connection with the Services or otherwise for or on behalf of Company.

 

2.         Ownership Rights; Proprietary Information; Publicity .

 

a.     Company shall own all right, title and interest (including all intellectual property rights of any sort throughout the world) relating to any and all inventions, works of authorship, designs, know-how, ideas and information made or conceived or reduced to practice, in whole or in part, by or for or on behalf of Consultant during the term of this Agreement that relate to the subject matter of or arise out of or in connection with the Services or any Proprietary Information (as defined below) (collectively, “Inventions”) and Consultant will promptly disclose and provide all Inventions to Company. Consultant hereby makes all assignments necessary to accomplish the foregoing ownership. Consultant shall assist Company, at Company’s expense, to further evidence, record and perfect such assignments, and to perfect, obtain, maintain, enforce and defend any rights assigned. Consultant hereby irrevocably designates and appoints Company as its agents and attorneys-in-fact, coupled with an interest, to act for and on Consultant’s behalf to execute and file any document and to do all other lawfully permitted acts to further the foregoing with the same legal force and effect as if executed by Consultant and all other creators or owners of the applicable Invention.

 

b.     Consultant agrees that all Inventions and all other business, technical and financial information (including, without limitation, the identity of and information relating to customers or employees) developed, learned or obtained by or on behalf of Consultant during the period that Consultant is to be providing the Services that relate to Company or the business or demonstrably anticipated business of Company or in connection with the Services or that are received by or for Company in confidence, constitute “Proprietary Information.” Proprietary information also includes information received in confidence by the Company from its customers or suppliers or other third parties. Consultant shall hold in confidence and not disclose or, except in performing the Services, use or permit to be used any Proprietary Information. However, Consultant shall not be obligated under this paragraph with respect to information Consultant can document is or becomes readily publicly available without restriction through no fault of Consultant, provided that Consultant must promptly notify Company of any knowledge of the same. Upon termination or as otherwise requested by Company, Consultant will promptly provide to Company all items and copies containing or embodying Proprietary Information, except that Consultant may keep its personal copies of its compensation records and this Agreement. Consultant also recognizes and agrees that Consultant has no expectation of privacy with respect to Company’s telecommunications, networking or information processing systems (including, without limitation, stored computer files, email messages and voice messages) and that Consultant’s activity, and any files or messages, on or using any of those systems may be monitored at any time without notice.

 

 

 

 

c.     As additional protection for Proprietary Information, Consultant agrees that during the period over which it is to be providing the Services and for one (1) year thereafter, Consultant will not directly or indirectly encourage or solicit any employee or consultant of Company to leave Company for any reason.

 

d.     To the extent allowed by law, Section 2(a) and any license granted Company hereunder includes all rights of paternity, integrity, disclosure and withdrawal and any other rights that may be known as or referred to as “moral rights,” “artist’s rights,” “droit moral,” or the like (collectively, “Moral Rights”). Furthermore, Consultant agrees that notwithstanding any rights of publicity, privacy or otherwise (whether or not statutory) anywhere in the world, and without any further compensation, Company may and is hereby authorized to (and to allow others to) use Consultant’s name in connection with promotion of its business, products or services. To the extent any of the foregoing is ineffective under applicable law, Consultant hereby provides any and all ratifications and consents necessary to accomplish the purposes of the foregoing to the extent possible and agrees not to assert any Moral Rights with respect thereto. Consultant will confirm any such ratifications and consents from time to time as requested by Company. If any other person is in any way involved in any Services, Consultant will obtain the foregoing ratifications, consents and authorizations from such person for Company’s exclusive benefit.

 

e.     If any part of the Services or Inventions or information provided hereunder is based on, incorporates, or is an improvement or derivative of, or cannot be reasonably and fully made, used, reproduced, distributed and otherwise exploited without using or violating technology or intellectual property rights owned by or licensed to Consultant (or any person involved in the Services) and not assigned hereunder, Consultant hereby grants Company and its successors a perpetual, irrevocable, worldwide royalty-free, non-exclusive, sublicensable right and license to exploit and exercise all such technology and intellectual property rights in support of Company’s exercise or exploitation of the Services, Inventions, other work or information performed or provided hereunder, or any assigned rights (including any modifications, improvements and derivatives of any of them).

 

 

 

 

3.        Warranties and Other Obligations . Consultant represents, warrants and covenants that: (i) the Services will be performed in a professional and workmanlike manner and that none of such Services nor any part of this Agreement is or will be inconsistent with any obligation Consultant may have to others; (ii) all work under this Agreement shall be Consultant’s original work and none of the Services or Inventions nor any development, use, production, distribution or exploitation thereof will infringe, misappropriate or violate any intellectual property or other right of any person or entity (including, without limitation, Consultant); (iii) Consultant has the full right to allow it to provide Company with the assignments and rights provided for herein (and has written enforceable agreements with all persons necessary to give it the rights to do the foregoing and otherwise fully perform this Agreement); (iv) Consultant shall comply with all applicable laws and Company safety rules in the course of performing the Services; and (v) if Consultant’s work requires a license, Consultant has obtained that license and the license is in full force and effect.

 

4.        Termination . If either party breaches a material provision of this Agreement the other party may terminate this Agreement upon ten (10) days’ notice, unless the breach is cured within the notice period. Company also may terminate this Agreement, with or without cause, and with or without notice five months after the Effective Date without breach of this Agreement. Consultant may terminate this Agreement upon fifteen (15) days’ notice. Upon termination of this Agreement, Company shall pay all amounts due for the Services completed prior to the termination date of this Agreement. Sections 2 (subject to the limitations set forth in Section 2(c)) through 9 of this Agreement and any remedies for breach of this Agreement shall survive any termination or expiration. Company may communicate the obligations contained in this Agreement to any other (or potential) client or employer of Consultant.

 

5.        Relationship of the Parties; Independent Contractor; No Employee Benefits; Taxes; Indemnification . Notwithstanding any provision hereof, Consultant is an independent contractor and is not an employee, agent, partner or joint venturer of Company and shall not bind nor attempt to bind Company to any contract. Nothing in this Agreement shall be interpreted or construed as creating or establishing a relationship of employer and employee between Company and Consultant, or any employee or agent of Consultant. Consultant shall accept any directions issued by Company pertaining to the goals to be attained and the results to be achieved by Consultant, but Consultant shall be solely responsible for the manner and hours in which the Services are performed under this Agreement. Consultant shall not be eligible to participate in any of Company’s employee benefit plans, fringe benefit programs, group insurance arrangements or similar programs. Company shall not provide workers’ compensation, disability insurance, Social Security or unemployment compensation coverage or any other statutory benefit to Consultant. Consultant acknowledges and agrees that Consultant is obligated to report as income all compensation received by Consultant pursuant to this Agreement, and Consultant agrees to and acknowledges the obligation to pay all taxes, including without limitation all federal and state income tax, social security taxes and unemployment, disability insurance and workers’ compensation applicable to Consultant and any person who performs Services in connection with this Agreement, and that Consultant will not be eligible for any employee benefits (nor does Consultant desire any of them) and expressly waives any entitlement to such benefits.

 

6.         Indemnification . Consultant agrees to indemnify and hold the Company, its affiliates and their respective directors, officers, agents and employees harmless to the extent of any obligation imposed on the Company (i) to pay withholding taxes or similar items . Consultant further agrees to indemnify and hold the Company, its affiliates and their respective directors, officers, agents and employees harmless from and against all claims, demands, losses, damages and judgments, including court costs and attorneys’ fees, arising out of or based upon any breach or alleged breach by Consultant of any representation, warranty, certification, covenant, obligation or other agreement set forth in this Agreement.

 

 

 

 

7.        Assignment . This Agreement and the services contemplated hereunder are personal to Consultant and Consultant shall not have the right or ability to assign, transfer or subcontract any rights or obligations under this Agreement without the written consent of Company. Any attempt to do so shall be void. Company may fully assign and transfer this Agreement in whole or part.

 

8.        Notice . All notices under this Agreement shall be in writing and shall be deemed given when personally delivered, or three days after being sent by prepaid certified or registered U.S. mail to the address of the party to be noticed as set forth herein or to such other address as such party last provided to the other by written notice.

 

9.        Whistleblower Protection. For the avoidance of doubt, Consultant understands that pursuant to the federal Defend Trade Secrets Act of 2016, Consultant shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.

 

10.       Miscellaneous .

 

a.     Any breach of Section 2 or 3 will cause irreparable harm to Company for which damages would not be an adequate remedy, and therefore, Company will be entitled to injunctive relief with respect thereto in addition to any other remedies.

 

b.     The failure of either party to enforce its rights under this Agreement at any time for any period shall not be construed as a waiver of such rights. No changes or modifications or waivers to this Agreement will be effective unless in writing and signed by both parties.

 

c.     In the event that any provision of this Agreement shall be determined to be illegal or unenforceable, that provision will be limited or eliminated to the minimum extent necessary so that this Agreement shall otherwise remain in full force and effect and enforceable.

 

d.     This Agreement shall be governed by and construed in accordance with the laws of the State of California without regard to the conflicts of laws provisions thereof.

 

 

 

 

e.     This Agreement constitutes the entire agreement and understanding between the Parties with respect to the subject matter herein and supersedes all prior written and oral agreements, discussions, or representations between the Parties, provided that Section 7 of the Employment Agreement between Consultant and the Company, dated February 27, 2018 (except as modified in Exhibit A to this Agreement), the Confidential Information and Invention Assignment Agreement between Consultant and the Company, dated February 27, 2018, and the Separation Agreement and Release between Consultant and Company executed simultaneously herewith, remain in full force and effect. Consultant represents and warrants that she is not relying on any statement or representation not contained in this Agreement. To the extent any terms set forth in any exhibit or schedule conflict with the terms set forth in this Agreement, the terms of this Agreement shall control unless otherwise expressly agreed by the Parties in such exhibit or schedule.

 

f.     Headings are used in this Agreement for reference only and shall not be considered when interpreting this Agreement.

 

g.     In any court action at law or equity that is brought by one of the Parties to this Agreement to enforce or interpret the provisions of this Agreement, the prevailing Party will be entitled to reasonable attorneys’ fees, in addition to any other relief to which that Party may be entitled.

 

h.     This Agreement may be signed in two counterparts, each of which shall be deemed an original, with the same force and effectiveness as though executed in a single document.

 

 

 

 

VIVEVE MEDICAL, INC.

 

 

 

 

 

 

Dated: May 30, 2018

By:

 /s/  Scott Durbin

 

Name:

  Scott Durbin

 

Title:

  Chief Executive Officer

     
     
     
  PATRICIA SCHELLER
     
     
     
Dated: May 30, 2018 /s/ Patricia Scheller
     
     
  Address:  
     

 

 

 

 

EXHIBIT A

 

 

TERM

 

The term during which Consultant will provide services under this Agreement will be for six (6) months from the effective date of this Agreement, unless terminated earlier under Section 4 above, whichever occurs first (the “ Consulting Period ”).

 

SERVICES

 

The services to be provided by Consultant will consist of advising on activities relating to ongoing patent litigation, ongoing employment litigation, corporate transactions and any other services as may be requested by the Company (collectively, the “Services”). The Services shall also include Consultant providing full cooperation with the Company in the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while the Consultant was employed by the Company, excluding any such claims or actions brought or asserted by the Company against Consultant. The Consultant’s full cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times.

 

FEES/EXPENSES  

 

The Company agrees to pay Consultant a fee of $16,000 per month (the “ Consulting Fee ”) for the Services performed during the Consulting Period. The Consulting Fee shall be earned and paid in arrears on a monthly basis.

 

E xpense reimbursement (limited to required, reasonable expenses authorized in writing by Company in advance, and payable after itemized invoice and delivery of receipts).

 

Consultant acknowledges and agrees that during the Consulting Period, Consultant shall not be entitled to any per diem fees addressed in Section 7(c) of the Employment Agreement between Consultant and the Company, dated February 27, 2018. Any such rights are suspended and superseded by the terms of this Agreement during the Consulting Period. Consultant acknowledges and agrees that immediately after the Consulting Period, Consultant’s rights and obligations under Section 7(c) of the Employment Agreement shall continue in full force and effect, and should Consultant be needed to cooperate with the Company after the end of the Consulting Period she will do so per the terms of Section 7(c) of the Employment Agreement.

Exhibit 10.2

SEPARATION AGREEMENT AND RELEASE

 

This Separation Agreement and Release (“Agreement”) is made by and between Patricia K. Scheller (“Executive”) and Viveve Medical, Inc., a Delaware corporation (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”) as of the Effective Date (as defined below).

 

RECITALS

 

WHEREAS, Executive and the Company entered into a Confidential Information and Invention Assignment Agreement, dated February 27, 2018 (the “Confidentiality Agreement”);

 

WHEREAS, Executive and the Company entered into an Employment Agreement, dated February 27, 2018 (the “Employment Agreement”);

 

WHEREAS, the Company and Executive have entered into a Stock Option Agreement for a grant dated October 24, 2012 (the “2012 Agreement”), an Incentive Stock Option Agreement dated September 26, 2014, an Incentive Stock Option Agreement dated December 16, 2015, an Incentive Stock Option Agreement dated December 23, 2016, an Incentive Stock Option Agreement dated January 23, 2018 and a Non-Qualified Stock Option Agreement dated January 23, 2018, each granting Executive the option to purchase shares of the Company’s common stock (the “Executive Option”) subject to the terms and conditions of the Company’s 2006 Amended and Restated Stock Plan (with respect to the 2012 Agreement) and the Company’s 2013 Stock Option and Incentive Plan and the Stock Option Agreement (with respect to the other agreements), and the Company and the Executive have entered into a Restricted Stock Agreement dated January 4, 2016 granting the Executive restricted shares of the Company’s common stock (the “RSA Agreement”) and the Company issued a warrant to Executive pursuant to a Common Stock Purchase Warrant dated February 17, 2015, (the “Warrant”, and collectively with the Executive Option, the option agreements referenced in this paragraph and the RSA Agreement, the “Stock Agreements”);

 

WHEREAS, Executive’s employment with the Company ended effective as of May 10, 2018 (the “Separation Date”);

 

WHEREAS, the Parties wish to resolve any and all disputes, claims, complaints, grievances, charges, actions, petitions, and demands that the Executive may have against the Company and any of the Releasees as defined below, including, but not limited to, any and all claims arising out of or in any way related to Executive’s employment with or separation from the Company;

 

NOW, THEREFORE, in consideration of the mutual promises made herein, the Company and Executive hereby agree as follows:

 

COVENANTS

 

1.       Resignation; Recitals . Executive does hereby resign her employment with the Company, and does further resign from any and all positions she holds as an officer of the Company and its subsidiaries, which resignation shall be effective immediately, provided that as consideration for the promises set forth herein, Executive’s obligation under the Employment Agreement to resign as a member of the Company’s Board of Directors (the “Board”) shall be waived until the Board’s 2019 annual meeting. Executive agrees that she shall resign from the Board no later than the Board’s 2019 annual meeting. Executive acknowledges and agrees that she shall not be eligible for director compensation. The Recitals set forth above are expressly incorporated into this Agreement.

 

Page 1 of 10

 

 

2.        Consideration . In exchange for Executive signing, not revoking, and complying with the terms of this Agreement, as well as other good and valuable consideration, the Company, consistent with the terms of the Employment Agreement, agrees to provide Executive with the following separation benefits:

 

a.      Severance Pay . The Company shall pay Executive severance pay (“Severance Pay”) consisting of salary continuation at Executive’s final base salary rate of $414,250.00 per year effective for the period from the date immediately following the Separation Date to and including the date which is twelve (12) months following the Separation Date (the “Severance Pay Period”). Severance Pay shall be subject to tax-related deductions and withholdings. The Company shall pay Executive Severance Pay on its regular payroll dates; provided that the Company shall not be obligated to include Executive on the payroll before this Agreement becomes effective. If the Company does not make one or more payments of Severance Pay on a regular payroll date because this Agreement has not yet become effective, the Company shall make all such delayed payments by the first payroll date when it is practicable to do so after the Agreement becomes effective.

 

b.      Health Benefits . If Executive elects COBRA continuation coverage, the Company shall pay the COBRA premiums on behalf of Executive until the earliest of the following: (i) the end of the Severance Pay Period; (ii) Executive’s eligibility for group medical care coverage through other employment; or (iii) the end of Executive’s eligibility under COBRA for continuation coverage for medical care. Executive agrees to notify the Company promptly if Executive becomes eligible for group medical care coverage through another employer. Executive also agrees to respond promptly and fully to any reasonable requests for information by the Company concerning eligibility for such coverage. Executive may continue coverage for herself and any beneficiaries after the end of the Severance Pay Period at her own expense for the remainder of the COBRA continuation period, to the extent she and they remain eligible.

 

c.      Options Vesting . Executive shall continue to vest in each Executive Option through the earlier of (y) December 31, 2018 and (z) the date Executive ceases to be a Service Provider, as defined in the Plan (the “Vesting End Date”). On the Vesting End Date, the Company shall accelerate Executive’s vesting in each Executive Option as if she remained employed for an additional six (6) months from the Vesting End Date, as set forth in Paragraph 3 below.

 

d.      Computer . Executive shall be permitted to keep the computer provided to Executive by the Company, provided that the Company shall retain the right to wipe clean all or portions of such content at any time. Executive agrees to promptly make the computer available upon request by the Company for such purpose.

 

e.      Benefits . The Company agrees to pay Executive for all accrued but unused vacation or PTO (as applicable) through the Separation Date in accordance with applicable law.

 

Page 2 of 10

 

 

f.      Consulting Agreement . The Company agrees to enter into a Consulting Agreement with the Executive, the form of which is annexed as Exhibit A hereto, provided that Executive acknowledges and agrees that during the Consulting Period, as defined in the Consulting Agreement, Executive shall not be entitled to any per diem fees, addressed in Section 7(c) of the Employment Agreement, but instead shall be compensated or reimbursed per the terms of the Consulting Agreement. Executive acknowledges that her cooperation obligations with the Company remain in full force and effect both during and after the term of her consulting agreement, with any compensation , fees or reimbursement during the Consulting Period governed by the Consulting Agreement.   Executive acknowledges and agrees that immediately after the Consulting Period, Consultant’s rights and obligations under Section 7(c) of the Employment Agreement shall continue in full force and effect, and should Executive be needed to cooperate with the Company after the end of the Consulting Period she will do so per the terms of Section 7(c) of the Employment Agreement.

 

3.       Equity . The Parties agree that as of the Separation Date, 335,626 of the shares subject to the Executive Options have vested. As consideration for Executive’s releases and other agreements hereunder, the Company agrees to allow Executive to continue vesting in the Executive Options until the Vesting End Date (the “Continued Vesting Shares”). In addition, on the Vesting End Date, the Company shall accelerate Executive’s vesting in each Executive Option as if Executive remained employed for an additional six (6) months (the “Accelerated Shares”), and no more, such that, including the Accelerated Shares, Executive shall be vested in a total of 516,149 shares as of the Vesting End Date, provided that the Vesting End Date is December 31, 2018. The Parties agree that the remainder of the Executive Option shall remain unvested following the acceleration and shall lapse. Executive has no interest or right to such unvested shares. The Parties further agree that Executive ceased being an employee as of the Separation Date and that, except as expressly set forth in this Agreement (the Continued Vesting Shares and Accelerated Shares), Executive did not and shall not vest in any additional portion of the Executive Option or otherwise obtain additional equity or debt interest in the Company following the Separation Date. Executive shall have twelve (12) months from the Separation Date to exercise the Continued Vesting Shares and Accelerated Shares. Executive acknowledges that, other than the Continued Vesting Shares, Accelerated Shares, equity that Executive purchased as part of the Employee Stock Purchase Plan, equity offerings, and restricted stock units granted in lieu of cash compensation during her employment with the Company, Executive has no other equity or debt interest in the Company of any kind, including but not limited to, any interest in stock, stock options, or other form of profit participation.

 

EMPLOYEE UNDERSTANDS THAT NEITHER THIS AGREEMENT NOR THE COURSE OF EMPLOYEE’S EMPLOYMENT WITH THE COMPANY, OR ANY OTHER SERVICE TO THE COMPANY, GIVE OR GAVE EMPLOYEE ANY RIGHT, CONTINUING OR OTHERWISE, TO THE REVENUES AND/OR PROFITS OF THE COMPANY AND/OR ANY OTHER RELEASEE (AS DEFINED BELOW) OR ANY OTHER INTEREST, ECONOMIC OR OTHERWISE, IN THE COMPANY AND/OR ANY OTHER RELEASEE (AS DEFINED BELOW).

 

4.       Benefits . Other than as specifically set forth in this Agreement, Executive agrees that Executive’s participation in all benefits and incidents of employment, including, but not limited to, vesting in stock, and the accrual of bonuses, vacation, and paid time off, ceased as of the Separation Date. Executive’s health and dental insurance benefits, if any, shall cease on the last day of May 2018, subject to Executive’s right to continue Executive’s coverage under COBRA.

 

Page 3 of 10

 

 

5.       Payment of Salary and Receipt of All Benefits . Executive acknowledges and represents that, other than the consideration set forth in this Agreement and consulting fees per the Consulting Agreement, the Company has paid or provided all salary, wages, bonuses, accrued vacation/paid time off, premiums, leaves, housing allowances, relocation costs, interest, severance, outplacement costs, fees, reimbursable expenses, commissions, stock, stock options, vesting, and any and all other benefits and compensation due to Executive. Executive specifically represents that Executive is not due to receive any commissions or other incentive compensation from the Company other than as set forth in this Agreement.

 

6.       Release of Claims . Executive agrees that the foregoing consideration represents settlement in full of all outstanding obligations owed to Executive by the Company and its current and former officers, directors, employees, agents, investors, attorneys, shareholders, administrators, affiliates, benefit plans, plan administrators, insurers, trustees, divisions, and subsidiaries, and predecessor and successor corporations and assigns (collectively, the “Releasees”). Executive, on Executive’s own behalf and on behalf of Executive’s respective heirs, family members, executors, agents, and assigns, hereby and forever releases the Releasees from, and agrees not to sue concerning, or in any manner to institute, prosecute, or pursue, any claim, complaint, charge, duty, obligation, demand, or cause of action relating to any matters of any kind, whether presently known or unknown, suspected or unsuspected, that Executive may possess against any of the Releasees arising from any omissions, acts, facts, or damages that have occurred up until and including the Effective Date of this Agreement, including, without limitation:

 

a.     any and all claims relating to or arising from Executive’s employment relationship with the Company and the termination of that relationship;

 

b.     any and all claims relating to, or arising from, Executive’s right to purchase, or actual purchase of shares of stock of the Company, including, without limitation, any claims for fraud, misrepresentation, breach of fiduciary duty, breach of duty under applicable state corporate law, and securities fraud under any state or federal law;

 

c.     any and all claims for wrongful discharge of employment; termination in violation of public policy; discrimination; harassment; retaliation; breach of contract, both express and implied; breach of covenant of good faith and fair dealing, both express and implied; commission payments; promissory estoppel; negligent or intentional infliction of emotional distress; fraud; negligent or intentional misrepresentation; negligent or intentional interference with contract or prospective economic advantage; unfair business practices; defamation; libel; slander; negligence; personal injury; assault; battery; invasion of privacy; false imprisonment; conversion; and disability benefits;

 

d.     any and all claims for violation of any federal, state, or municipal statute, including, but not limited to, Title VII of the Civil Rights Act of 1964; the Civil Rights Act of 1991; the Rehabilitation Act of 1973; the Americans with Disabilities Act of 1990; the Equal Pay Act; the Fair Labor Standards Act; the Fair Credit Reporting Act; the Employee Retirement Income Security Act of 1974; the Worker Adjustment and Retraining Notification Act; the Family and Medical Leave Act; the Sarbanes-Oxley Act of 2002; the Immigration Control and Reform Act; the California Family Rights Act; the California Labor Code; the California Workers’ Compensation Act; the California Fair Employment and Housing Act; and any other similar statutes, regulations or laws;

 

Page 4 of 10

 

 

e.     any and all claims for violation of the federal or any state constitution;

 

f.     any and all claims arising out of any other laws and regulations relating to employment or employment discrimination;

 

g.     any claim for any loss, cost, damage, or expense arising out of any dispute over the nonwithholding or other tax treatment of any of the proceeds received by Executive as a result of this Agreement; and

 

h.     any and all claims for attorneys’ fees and costs.

 

Executive agrees that the release set forth in this section shall be and remain in effect in all respects as a complete general release as to the matters released, provided, however, that Executive does not release any claims to any rights for indemnification by the Company that she may have as set forth in Section 15 hereof. This release does not extend to any obligations incurred under this Agreement. This release does not release claims that cannot be released as a matter of law. Executive represents that Executive has made no assignment or transfer of any right, claim, complaint, charge, duty, obligation, demand, cause of action, or other matter waived or released by this section.

 

7.        Acknowledgment of Waiver of Claims under ADEA . Executive acknowledges that Executive is waiving and releasing any rights Executive may have under the Age Discrimination in Employment Act of 1967 (“ADEA”), and that this waiver and release is knowing and voluntary. Executive agrees that this waiver and release does not apply to any rights or claims that may arise under the ADEA after the Effective Date of this Agreement. Executive acknowledges that the consideration given for this waiver and release is in addition to anything of value to which Executive was already entitled. Executive further acknowledges that Executive has been advised by this writing that: (a) Executive should consult with an attorney prior to executing this Agreement; (b) Executive has twenty-one (21) days within which to consider this Agreement; (c) Executive has seven (7) days following Executive’s execution of this Agreement to revoke this Agreement; (d) this Agreement shall not be effective until after the revocation period has expired; and (e) nothing in this Agreement prevents or precludes Executive from challenging or seeking a determination in good faith of the validity of this waiver under the ADEA, nor does it impose any condition precedent, penalties, or costs for doing so, unless specifically authorized by federal law. In the event Executive signs this Agreement and returns it to the Company in less than the 21-day period identified above, Executive hereby acknowledges that Executive has freely and voluntarily chosen to waive the time period allotted for considering this Agreement. Executive acknowledges and understands that revocation must be accomplished by a written notification to the person executing this Agreement on the Company’s behalf that is received prior to the eighth day after Executive signs this Agreement. The parties agree that changes, whether material or immaterial, do not restart the running of the 21-day period.

 

Page 5 of 10

 

 

8.       California Civil Code Section 1542 . Executive acknowledges that Executive has been advised to consult with legal counsel and is familiar with the provisions of California Civil Code Section 1542, a statute that otherwise prohibits the release of unknown claims, which provides as follows:

 

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.

 

Executive, being aware of said code section, agrees to expressly waive any rights Executive may have thereunder, as well as under any other statute or common law principles of similar effect.

 

9.       No Pending or Future Lawsuits . Executive represents that Executive has no lawsuits, claims, or actions pending in Executive’s name, or on behalf of any other person or entity, against the Company or any of the other Releasees. Executive also represents that Executive does not intend to bring any claims on Executive’s own behalf or on behalf of any other person or entity against the Company or any of the other Releasees.

 

10.      Confidentiality . Executive agrees to maintain in complete confidence the existence of this Agreement, the contents and terms of this Agreement, and the consideration for this Agreement (hereinafter collectively referred to as “Separation Information”). Except as required by law, Executive may disclose Separation Information only to Executive’s immediate family members, the Court in any proceedings to enforce the terms of this Agreement, Executive’s attorney(s), and Executive’s accountant and any professional tax advisor to the extent that they need to know the Separation Information in order to provide advice on tax treatment or to prepare tax returns, and must prevent disclosure of any Separation Information to all other third parties. Executive agrees that Executive will not publicize, directly or indirectly, any Separation Information.

 

11.      Trade Secrets and Confidential Information/Company Property . Executive reaffirms and agrees to observe and abide by the terms of the Confidentiality Agreement, specifically including the provisions therein regarding nondisclosure of the Company’s trade secrets and confidential and proprietary information, and nonsolicitation of Company employees; provided that Executive hereby acknowledges receipt of the following notice required pursuant to 18 U.S.C § 1833(b)(1): “An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.” Executive acknowledges that during the course of Executive’s employment with the Company Executive had access to a number of highly confidential materials and Executive specifically represents that Executive shall refrain from using any such confidential information in the future. Executive affirms that Executive has returned all documents and other items provided to Executive by the Company, developed or obtained by Executive in connection with Executive’s employment with the Company, or otherwise belonging to the Company.

 

12.      No Cooperation . Executive agrees that Executive will not knowingly encourage, counsel, or assist any attorneys or their clients in the presentation or prosecution of any disputes, differences, grievances, claims, charges, or complaints by any third party against any of the Releasees, unless under a subpoena or other court order to do so or as related directly to the ADEA waiver in this Agreement. Executive agrees both to immediately notify the Company upon receipt of any such subpoena or other legal process, and to furnish, within three (3) business days of its receipt, or as quickly as practicable a copy of such subpoena or other legal process. If approached by anyone for counsel or assistance in the presentation or prosecution of any disputes, differences, grievances, claims, charges, or complaints against any of the Releasees, Executive shall state no more than that Executive cannot provide counsel or assistance.

 

Page 6 of 10

 

 

13.      Nondisparagement . Executive agrees to refrain from any disparagement, defamation, libel, or slander of any of the Releasees, and agrees to refrain from any tortious interference with the contracts and relationships of any of the Releasees. Executive agrees to refrain from making, either directly or indirectly, any negative, damaging or otherwise disparaging communications concerning the Company or its services to any of the clients of the Company. Executive shall not use any Company information that is confidential either under applicable law or the Confidentiality Agreement to which Executive had access during the scope of Executive’s employment with the Company in order to communicate with or solicit any of the Company’s current or prospective clients. The Company shall instruct its Board and officers during the pendency of their engagement and/or employment with the Company to refrain at any time from any disparagement, defamation, libel, or slander of the Executive, and to refrain at any time from any tortious interference with the contracts and relationships of the Executive.

 

14.      Protected Disclosure . Nothing contained in this Agreement limits Executive’s ability to file a charge or complaint with any federal, state or local governmental agency or commission (a “Government Agency”). In addition, nothing contained in this Agreement limits Executive’s ability to communicate with any Government Agency or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including Executive’s ability to provide documents or other information, without notice to the Company, nor does anything contained in this Agreement apply to truthful testimony in litigation. If Executive’s files any charge or complaint with any Government Agency and if the Government Agency pursues any claim on Executive’s behalf, or if any other third party pursues any claim on Executive’s behalf, Executive waives any right to monetary or other individualized relief (either individually, or as part of any collective or class action).

 

15.      Indemnification . If in the future a third party should assert a claim against Executive which relates to Executive’s actions as an employee of the Company prior to the termination of Executive’s employment, the Company shall continue to indemnify Executive to the fullest extent under the Company’s by-laws, Delaware law, and the Company’s Directors and Officers insurance policy for any costs, attorney’s fees, settlements or damages which Executive might incur in connection with that claim.

 

16.      Breach . In addition to the rights provided in the “Attorneys’ Fees” section below, Executive acknowledges and agrees that any material breach of this Agreement, or of any provision of the Confidentiality Agreement, shall entitle the Company immediately to recover and/or cease providing the consideration provided to Executive under this Agreement and to obtain damages, except as provided by law.

 

17.      No Admission of Liability . Executive understands and acknowledges that this Agreement constitutes a compromise and settlement of any and all actual or potential disputed claims by Executive. No action taken by the Company hereto, either previously or in connection with this Agreement, shall be deemed or construed to be (a) an admission of the truth or falsity of any actual or potential claims or (b) an acknowledgment or admission by the Company of any fault or liability whatsoever to Executive or to any third party.

 

Page 7 of 10

 

 

18.      Costs . The Parties shall each bear their own costs, attorneys’ fees, and other fees incurred in connection with the preparation of this Agreement.

 

19.      Tax Consequences . The Company makes no representations or warranties with respect to the tax consequences of the payments and any other consideration provided to Executive or made on Executive’s behalf under the terms of this Agreement. Executive agrees and understands that Executive is responsible for payment, if any, of local, state, and/or federal taxes on the payments and any other consideration provided hereunder by the Company and any penalties or assessments thereon. Executive further agrees to indemnify and hold the Company harmless from any claims, demands, deficiencies, penalties, interest, assessments, executions, judgments, or recoveries by any government agency against the Company for any amounts claimed due on account of (a) Executive’s failure to pay or delayed payment of federal or state taxes, or (b) damages sustained by the Company by reason of any such claims, including attorneys’ fees and costs.

 

20.      Authority . The Company represents and warrants that the undersigned has the authority to act on behalf of the Company and to bind the Company and all who may claim through it to the terms and conditions of this Agreement. Executive represents and warrants that Executive has the capacity to act on Executive’s own behalf and on behalf of all who might claim through Executive to bind them to the terms and conditions of this Agreement. Each Party warrants and represents that there are no liens or claims of lien or assignments in law or equity or otherwise of or against any of the claims or causes of action released herein.

 

21.      No Representations . Executive represents that Executive has had an opportunity to consult with an attorney, and has carefully read and understands the scope and effect of the provisions of this Agreement. Executive has not relied upon any representations or statements made by the Company that are not specifically set forth in this Agreement.

 

22.      Severability . In the event that any provision or any portion of any provision hereof or any surviving agreement made a part hereof becomes or is declared by a court of competent jurisdiction or arbitrator to be illegal, unenforceable, or void, this Agreement shall continue in full force and effect without said provision or portion of provision.

 

23.      Attorneys’ Fees . In the event that either Party brings an action to enforce or effect its rights under this Agreement, the prevailing Party shall be entitled to recover its costs and expenses, including the costs of mediation, arbitration, litigation, court fees, and reasonable attorneys’ fees incurred in connection with such an action.

 

24.      Entire Agreement . This Agreement represents the entire agreement and understanding between the Company and Executive concerning the subject matter of this Agreement and Executive’s employment with and separation from the Company and the events leading thereto and associated therewith, and supersedes and replaces any and all prior agreements and understandings concerning the subject matter of this Agreement and Executive’s relationship with the Company, with the exception of the Confidentiality Agreement, Section 7 of the Employment Agreement (except as modified herein) and the Stock Agreements (except as modified herein).

 

25.      No Oral Modification . This Agreement may only be amended in a writing signed by Executive and a duly authorized representative of the Company.

 

Page 8 of 10

 

 

26.      Governing Law . This Agreement shall be governed by the laws of the State of California, without regard for choice-of-law provisions. Executive and the Company each consent to personal and exclusive jurisdiction and venue in the State of California.

 

27.      Effective Date . Executive understands that this Agreement shall be null and void if not executed by Executive within twenty-one (21) days.  In the event that Executive signs this Agreement within twenty-one days, then the Company has seven days after such date to countersign the Agreement and return a fully-executed version to Executive. This Agreement will become effective on the eighth (8th) day after Executive signed this Agreement, so long as it has been signed by the Company and has not been revoked before that date (the “Effective Date”).

 

28.      Counterparts . This Agreement may be executed in counterparts and by facsimile, and each counterpart and facsimile shall have the same force and effect as an original and shall constitute an effective, binding agreement on the part of each of the undersigned.

 

29.      Voluntary Execution of Agreement . Executive understands and agrees that Executive executed this Agreement voluntarily, without any duress or undue influence on the part or behalf of the Company or any third party, with the full intent of releasing all of Executive’s claims against the Company and any of the other Releasees. Executive acknowledges that:

 

  (a) Executive has read this Agreement;
     
 

(b)

Executive has been represented in the preparation, negotiation, and execution of this Agreement by legal counsel of Executive’s own choice or has elected not to retain legal counsel;

 

 

(c)

Executive understands the terms and consequences of this Agreement and of the releases it contains; and

     
  (d) Executive is fully aware of the legal and binding effect of this Agreement.

 

[Signature page follows; Remainder of page intentionally left blank]

 

Page 9 of 10

 

 

IN WITNESS WHEREOF, the Parties have executed this Agreement on the respective dates set forth below.

 

 

 

 

PATRICIA K. SCHELLER, an individual

 

 

 

     

Dated:    May 25, 2018

/s/ Patricia K. Scheller

 

Patricia K. Scheller

 

 

 

     
     
  Viveve Medical, Inc.
     
     
Dated:    May 30, 2018 By /s/ Scott Durbin
    Name:  Scott Durbin
    Its:  Chief Executive Officer

 

 

[Signature Page to Separation Agreement and Release]

Exhibit 99.1

 

Viveve Announces Settlement of Patent Infringement Litigation w ith Thermi

 

 

ENGLEWOOD, CO – June 4 , 2018 - Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that is has reached a settlement to resolve the patent litigation that it filed in 2016 against ThermiGen, LLC, ThermiAesthetics, LLC, and Dr. Red Alinsod in the U.S. District Court for the Eastern District of Texas citing infringement of Viveve’s intellectual property ( Viveve, Inc. v. ThermiGe n , LLC, No.2:16-1189 ). Under the settlement, Viveve will receive a monetary payment and on-going royalty, as well as other mutual agreements relating to certain intellectual property owned by the companies.

 

“We are extremely pleased to have reached a favorable settlement in this case, which concludes the patent litigation in defense of our intellectual property rights against Thermi. As we continue to advance our global clinical and commercialization strategy, we intend to continue to take action to protect our valuable intellectual property portfolio,“ said Scott Durbin, chief executive officer and director of Viveve.

 

About Viveve

 

Viveve Medical, Inc. is a women's intimate health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. The internationally patented Viveve® System, that delivers the Viveve treatment, incorporates clinically-proven cryogen-cooled, monopolar radiofrequency (CMRF) technology to uniformly deliver volumetric heating while gently cooling surface tissue to generate robust neocollagenesis in a single 30-minute in-office session.

 

International regulatory approvals and clearances have been received for vaginal laxity and/or improvement in sexual function indications from over 55 countries. Viveve received approval of an Investigational Device Exemption (IDE) application from the U.S. Food and Drug Administration (FDA) in March of 2018 to proceed with VIVEVE II, a multicenter, randomized, double-blind, sham-controlled study to assess improvement of sexual function in women following childbirth. Initiation of the trial began in the second quarter of 2018 and if successful, could support a marketing application for a new U.S. commercial indication. Currently, in the United States, the Viveve System is cleared by the FDA for use in general surgical procedures for electrocoagulation and hemostasis. 

 

Viveve has submitted an Investigational Trial Application to the Canadian Ministry of Health and plans to submit an IDE to the FDA to conduct two independent multicenter randomized registration trials (LIBERATE-International and LIBERATE-U.S. respectively) for use of the CMRF device in stress urinary incontinence treatment.

 

InControl Products by Viveve are FDA cleared medical devices that treat stress, urge, and mixed incontinence conditions and products to improve pelvic floor strength. Viveve exclusively distributes InControl Medical's products to healthcare providers in the United States.

 

 

 

 

For more information visit Viveve's website at  www.viveve.com .

 

Safe Harbor Statement

 

All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. While management has based any forward-looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, the fluctuation of global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic and current reports available for review at www.sec.gov. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

 

Viveve is a registered trademark of Viveve, Inc.

 

Investor Relations contact:

Sarah McCabe

Stern Investor Relations, Inc.

(212) 362-1200

sarah@sternir.com

 

Amato and Partners, LLC

Investor Relations Counsel

admin@amatoandpartners.com

 

Media contact:

Kelley Wakelee

Berry & Company Public Relations

(212) 253-8881

kwakelee@berrypr.com